Nitrated-fatty acids modulation of type II diabetes
US10258589B2 · kind B2 · utility
8Cited by
36References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2017 |
| Grant date | Apr 16, 2019 |
| Priority date | — |
| Expiry date | Jun 21, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Nitro oleic acid and related metabolites are agonists of PPAR-γ. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-γ, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-γ.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.